ICICI Prudential Healthcare Fund

A Sectoral/Thematic Fund scheme from ICICI Prudential Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF109KC1GH2).

NAV ₹48.2100 on 16 November 2026.

Expense ratio

Total expense ratio 1.30% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.88%, brokerage 0.07%, transaction costs 0.01%, statutory levies including GST 0.34%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year9.5%13.9%-10.6%0.180.19
3 years22.2%13.9%-16.2%1.091.07
5 years17.5%13.3%-16.2%0.790.77

Too little NAV history for the 10-year figures.

Category rank: 6th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 96.5% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 10.48%
  2. Dr. Reddy's Laboratories Limited — 9.64%
  3. Cipla Limited — 5.78%
  4. Biocon Limited — 5.30%
  5. Apollo Hospitals Enterprise Limited — 4.69%
  6. Alkem Laboratories Limited — 4.61%
  7. Mankind Pharma Limited — 4.50%
  8. Medplus Health Services Limited — 4.30%
  9. Syngene International Limited — 3.76%
  10. Cohance Lifesciences Limited — 3.67%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.